Date: 2016-10-16
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Pfizer (USA - NY)
Product: lorlatinib (PF-06463922)
Action
mechanism: tyrosine kinase inhibitor. Lorlatinib (PF-06463922) is an Alk/ros1 tyrosine kinase inhibitor.
Disease: ALK-positive non small cell lung cancer (NSCLC) and ROS1-positive NSCLC
Therapeutic area: Cancer - Oncology
Country: Australia, Belgium, Canada, France, Germany, Hong Kong, Italy, Japan, Republic of Korea, Singapore, Spain, Switzerland, Taiwan, USA
Trial
details: Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients . (NCT01970865)
Latest
news: * On October 16, 2016, a Phase 2 trial sponsored by Pfizer was published on the NIH website ClinicalTrials.gov for lorlatinib and is currently recruiting participants.
